灯盏花素联合长春西汀治疗急性脑梗死的临床观察  

Clinical Observation of Breviscapine Combined with Vinpocetine in the Treatment of Acute Cerebral Infarction

作　　者：冯诗婷[1] 李丽[1] 林云[2] 

机构地区：[1]海南医学院第一附属医院药剂科,海口570102 [2]海南医学院第一附属医院心血管科,海口570102

出　　处：《中国药房》2017年第26期3678-3681,共4页China Pharmacy

摘　　要：目的:探讨灯盏花素联合长春西汀治疗急性脑梗死的临床疗效及安全性。方法:选取2014年1月-2015年12月我院收治的急性脑梗死患者80例作为研究对象,按照随机数字表法分为对照组和观察组,各40例。对照组患者给予长春西汀注射液20mL+0.9%氯化钠注射液250 mL,ivgtt,qd;观察组患者在对照组基础上间隔2~3 h给予灯盏花素注射液20 mL+5%葡萄糖注射液250 mL,ivgtt,qd。两组患者均治疗2周。观察两组患者的临床疗效,治疗前后的血清和肽素、N端前脑钠肽(NT-pro BNP)、白蛋白钴结合(ACB)值以及欧洲卒中量表(ESS)和功能独立性评定(FIM)评分,并记录不良反应发生情况。结果:观察组患者临床总有效率(90.0%)明显高于对照组(67.5%),差异有统计学意义(P<0.05)。治疗前,两组患者血清和肽素、NT-pro BNP、ACB值和ESS、FIM评分比较,差异均无统计学意义(P>0.05);治疗后,两组患者血清和肽素和NT-pro BNP水平均明显降低,ACB值、ESS和FIM评分明显升高,且观察组患者改善情况均明显优于对照组,差异均有统计学意义(P<0.05)。两组患者治疗过程中未见明显的不良反应发生。结论:灯盏花素联合长春西汀可明显改善急性脑梗死患者的神经功能,临床疗效较好,且安全性较高。OBJECTIVE： To investigate clinical efficacy and safety of breviscapine combined with vinpocetine in the treatment of acute cerebral infraction. METHODS： A total of 80 patients with acute cerebral infraction were selected from our hospital during Jan. 2014-Dec. 2015, and then divided into observation group and control group according to random number table, with 40 cases in each group. Control group was given Vinpocetine injection 20 mL＋0.9% Sodium chloride injection 250 mL, ivgtt, qd. Observa- tion group was additionally given Breviscapine injection 20 mL＋5% Glucose injection 250 mL, ivgtt, qd, at intervals of 2-3 h on the basis of control group. Both groups were treated for 2 weeks. Clinical efficacies as well as serum copeptin, NT-proBNP, albu- min cobalt binding （ACB） value, European stroke scale （ESS） and functional independence measurement （FIM） score before and after treatment were observed in 2 groups, and the occurrence of ADR was recorded. RESULTS： Total response rate of observation group （90.0%） was significantly higher than that of control group （67.5%）, with statistical significance （P〈0.05）. Before treat- ment, there was no statistical significance in serum peptide, NT-proBNP, ACB value, ESS or FIM score between 2 groups （P〉 0.05）. After treatment, serum copeptin and NT-proBNP levels of 2 groups were decreased significantly, while ACB value, ESS and FIM score were increased significantly; the improvement of observation group was significantly better than that of control group, with statistical significance （P〈0.05）. No obvious ADR was found in 2 groups. CONCLUSIONS： Breviscapine combined with vinpocetine can improve neurological function of acute cerebral infraction patients and show good therapeutic efficacy with good safety.

关 键 词：灯盏花素 长春西汀 急性脑梗死 和肽素 N端前脑钠肽 缺血修饰性白蛋白 

分 类 号：R743.3[医药卫生—神经病学与精神病学]